COMPLETED

Development of Charcot Marie Tooth Disease (CMT) Pediatric Scale for Children With CMT

Conditions

Quick Navigation

Study Overview

This clinical trial focuses on testing the efficacy of different digital interventions to promote re-engagement in cancer-related long-term follow-up care for adolescent and young adult (AYA) survivors of childhood cancer.

Description

The primary goal of this project is to develop and test a Charcot Marie Tooth disease (CMT) Pediatric Scale for use in evaluation in natural history CMT study.

Official Title

Development and Validation of CMT Pediatric Scale for Children With Charcot Marie Tooth

Quick Facts

Study Start:2010-04

Study Completion:2025-09

Study Type:Not specified

Phase:Not Applicable

Enrollment:Not specified

Status:COMPLETED

Study ID

NCT01203085

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Ages Eligible for Study:Not specified to 21 Years

Sexes Eligible for Study:ALL

Accepts Healthy Volunteers:No

Standard Ages:CHILD, ADULT

Inclusion Criteria	Exclusion Criteria
* Children (\< 21 years of age) * Known or probable inherited neuropathies classified as CMT1, CMT2, or CMT4	* Known diagnoses of acquired neuropathy including toxic (e. g. medication related neuropathies); metabolic (e.g. diabetic), immune mediated or inflammatory \[acute inflammatory demyelinating polyradiculoneuropathy (AIDP) or chronic inflammatory demyelinating polyneuropathy (CIDP)\] polyneuropathies; neuropathy related to leukodystrophy, congenital muscular dystrophy; and patients with severe general medical conditions. * Entirely normal conduction velocities of upper and lower limbs as this suggests that the subject may not have a neuropathy.

Inclusion Criteria

Exclusion Criteria

* Children (\< 21 years of age)
* Known or probable inherited neuropathies classified as CMT1, CMT2, or CMT4

* Known diagnoses of acquired neuropathy including toxic (e. g. medication related neuropathies); metabolic (e.g. diabetic), immune mediated or inflammatory \[acute inflammatory demyelinating polyradiculoneuropathy (AIDP) or chronic inflammatory demyelinating polyneuropathy (CIDP)\] polyneuropathies; neuropathy related to leukodystrophy, congenital muscular dystrophy; and patients with severe general medical conditions.
* Entirely normal conduction velocities of upper and lower limbs as this suggests that the subject may not have a neuropathy.

Contacts and Locations

Principal Investigator

Michael E Shy, MD

PRINCIPAL_INVESTIGATOR

University of Iowa

Study Locations (Sites)

Stanford University

Palo Alto, California, 94305

United States

University of Connecticut/Connecticut Children's Medical Center

Hartford, Connecticut, 06106

United States

Nemours Children's Clinic

Orlando, Florida, 32827

United States

University of Iowa

Iowa City, Iowa, 52242

United States

University of Michigan

Ann Arbor, Michigan, 48109

United States

University of Rochester

Rochester, New York, 14642

United States

University of North Carolina

Chapel Hill, North Carolina, 27514

United States

Children's Hospital of Philadelphia

Philadelphia, Pennsylvania, 19104

United States

Seattle Children's Hospital

Seattle, Washington, 98105

United States

Collaborators and Investigators

Sponsor: University of Iowa

Michael E Shy, MD, PRINCIPAL_INVESTIGATOR, University of Iowa

Study Record Dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Registration Dates

Study Start Date2010-04

Study Completion Date2025-09

Study Record Updates

Study Start Date2010-04

Study Completion Date2025-09

Terms related to this study

Additional Relevant MeSH Terms

Charcot Marie Tooth Disease